Navigation Links
FDA funds pediatric trial testing genetically reprogrammed HSV to treat cancer
Date:10/12/2010

CINCINNATI A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S. Food and Drug Administration grant to support the research.

The Phase I trial at Cincinnati Children's Hospital Medical Center currently focuses on testing the safety of the agent HSV1716 in patients. The study includes young patients with solid tumors such as rhabdomyosarcoma or Ewing's sarcoma. These cancers have limited treatment options and survival rates under 30 percent when the cancers recur and spread to other parts of the body.

Survival curves for stubborn, metastatic childhood cancers have leveled off in the last decade, underscoring the need for new therapeutic approaches, says Timothy Cripe, M.D., Ph.D., principal investigator on the trial and a physician/researcher in division of Hematology/Oncology at Cincinnati Children's.

"We've exhausted our ability to improve cure rates with existing conventional therapies and we need new solutions," he said. "This is why we are testing HSV. It's a potent virus that has been manipulated genetically with the intent of making it safe for the patient. When you're trying to fight fire with fire you need something that is strong."

The $600,000 grant from FDA is part of a program encouraging clinical development of "orphan drugs" as new treatments for rare diseases or conditions. The HSV1716 virus being tested in this trial was developed by Crusade Laboratories of Glasgow, Scotland.

HSV1716 is similar to other viruses now under development by Dr. Cripe and colleagues at Cincinnati Children's in that certain genes are removed so the virus does not infect healthy dormant cells or cause the disease in the recipient. Instead, the genetic manipulation is designed to prompt the virus to target, infect and degrade only rapidly dividing cancer cells.

Genetic information also can be added to HSV that programs the virus
'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. NIH funds Center of Excellence for Molecular Hematology at Cincinnati Childrens
2. $1.5M grant funds research aimed at reducing strokes in children with sickle cell disease
3. NIH funds center at Arizona State to battle infectious diseases
4. French national research agency funds PREDIMOL project
5. NHGRI funds development of third generation DNA sequencing technologies
6. $22.5 million grant funds international study of membrane proteins
7. NSF funds innovative approach to biomimetic nanofiber bone regeneration
8. Gulf oil spill: NSF funds research on impacts to Florida Everglades
9. NSF funds Virginia Tech program to train researchers at intersection of engineering, biology
10. NIH funds multicenter glue grant to study enzyme function
11. California funds UCI basic research on stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... for delivering compounds that could positively impact ... may be possible, thanks to researchers in ... semi-soft vaginal suppository made from the seaweed-derived ... antiviral drug Tenofovir provides a woman-initiated, drug-delivery ... of sexually transmitted infections during unprotected heterosexual ...
(Date:8/28/2014)... August 28, 2014 Dyslexia, the most commonly ... a neurological reading disability that occurs when the ... don,t function normally. , The use of non-invasive ... activity is disrupted in dyslexia. However, most prior ... of brain regions, leaving a gap in our ...
(Date:8/28/2014)... the first person to alert the world to Global ... be captured and stored underground. He says that Carbon ... the best way to avoid global warming getting out ... (Columbia University, New York) made the call during his ... where 150 scientists are meeting to discuss Carbon Capture ...
Breaking Biology News(10 mins):Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Dyslexic readers have disrupted network connections in the brain 2Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2
... and molecular biologists, chemists, physicists, material scientists, computational modelers ... the newly funded Center for Lignocellulose Structure and Formation, ... Penn State. The DOE plans to fund the ... Cosgrove, professor of biology, will direct the Center in ...
... human brain stores some kinds of memories for a ... at things, our gray matter also creates temporary memories ... seconds these visual memories exist. For decades, scientists have ... grow gradually more imprecise over the course of several ...
... A new longitudinal study of children,s personality traits ... differently in girls and boys. The study, by ... of Hawaii at Manoa, and Purdue University, appears ... Child Development . The researchers looked ...
Cached Biology News:Center to investigate plant cells for better biomass fuels 2Some short-term memories die suddenly, no fading 2Sugar, spice and puppy dog tails: Developing sex-typed personality traits and interests 2
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides users ... said Mark Tess, PhD, Mycotoxin Product Manager for Charm Sciences. ... USDA-GIPSA inspection agencies that have a need to detect aflatoxin ... a matter of minutes with nothing but our equipment and ... grain before accepting it, but they no longer have to ...
(Date:8/28/2014)... Grove, PA (PRWEB) August 28, 2014 ... and create a culture that will allow individuals to ... are becoming increasingly important for employers looking to compete ... science industries are embracing this trend, as the sector ... fabric of a company, which will have real results ...
(Date:8/28/2014)... PARK, Calif. , Aug. 28, 2014 /PRNewswire/ ... focused on developing novel mid- to late-stage cardiovascular ... $7.0 million in its first round of financing. ... Biomedical Investments and Hercules Bioventures with participation from ... entrepreneur and pharmaceutical executive, Dr. Larry Hsu ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... sponges, IUDs, diaphragms-- women have many options for planning their ... men want to help out? They have only two options ... crucial for dating but get old in long-term relationships. ... that nobody is every calling them "Daddy" before they are ...
... PPD, Inc. (Nasdaq:,PPDI) will release its third quarter 2007 ... The earnings release will be available,on the PPD Web ... On Wednesday, October 24, at 9 a.m. ET, ... to discuss financial results and the,overall business environment. A ...
... 28 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ... interim results from a U.K. Phase Ia/Ib ... with advanced or,metastatic cancers is scheduled to ... (NCRI) conference on October 2, 2007 in ...
Cached Biology Technology:Of mice and men: new male contraceptives successful in rodents and humans 2PPD Announces Third Quarter 2007 Earnings Release, Webcast and Conference Call 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 2Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 3Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial 4
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Mouse monoclonal [HYB 232-02] to Protein S ( Abpromise for all tested applications). entrezGeneID: 5627 SwissProtID: P07225...
Simple operation and an easy-to-read LCD display characterize our Classic Light balances. * Taring range 0...1510 g...
... SLi 3 •3H 2 O Formula Weight: 881.42 ... pH 7.0): greater than or equal to 90% lambda max : 259 ... Spectral Ratios: A 232 /A 260 : 0.51 ... 280 /A 260 : 0.17 0.02 Storage: -20C ...
Biology Products: